People with type 2 diabetes derive benefit from earlier detection and treatment, suggests a decade-long follow-up of the Anglo-Danish-Dutch Study in General Practice of Intensive Treatment and Complication Prevention in Type 2 Diabetic Patients Identified by Screening(ADDITION-Europe).
"The 10-year follow-up findings support the use of intensive treatment of type 2 diabetes soon after diagnosis and have implications for policy relating to early detection and subsequent management of type 2 diabetes in primary care," said Simon Griffin, MD.
Griffin, the study lead from the University of Cambridge, UK, presented the findings at the virtual European Association for the Study of Diabetes (EASD) Annual Meeting 2020.
Although the difference in the primary outcome between the intensive treatment and routine care groups favored the former, the difference was not statistically significant.
Still, "It looks like early intensive treatment of multiple risk factors soon after diagnosis is safe and seems to lower cardiovascular events and mortality...patients benefit from early detection, and in turn, early treatment," Griffin emphasized.
Asked to comment, Andrew Boulton, MD, told Medscape Medical News that these results highlight the importance of recognizing type 2 diabetes not simply as a metabolic disease but as a cardiometabolic problem.
"The nonsignificance of these outcomes should not detract physicians in both primary and secondary care in their quest to achieve optimal control of not only diabetes, but also cholesterol, triglycerides, blood pressure, and body weight...and to avoid therapeutic inertia, which is frequently reported," said Boulton, of University of Manchester and Manchester Royal Infirmary, UK.
The 10-year results from ADDITION-Europe were also published in Lancet Diabetes & Endocrinology. And in an accompanying editorial, Takayoshi Sasako, MD, a diabetologist from the University of Tokyo, Japan, and colleagues say the effects of an intensive treatment program on cardiovascular outcomes and mortality seen at 5 years were largely sustained for an additional 5 years.
"Despite the lack of statistical significance probably partly due to improvements in clinical practice when the study was done these findings lend support to early multifactorial intervention in type 2 diabetes," they stress.
Sasako and colleagues add that it will be interesting to see whether the postulated benefits from intensive multifactorial treatment in ADDITION-Europe will become more evident in the next decade or whether they will fade, as in the Veterans Affairs Diabetes Trial (VADT).
"It will also be important to follow-up the ADDITION-Europe study cohort for the incidence of diabetes complications and mortality in the next decade and beyond, because such a prospective cohort in which patients are exposed to good control of risk factors in the first decade after diagnosis is rare," they add.
ADDITION-Europe aimed to assess the long-term effects of guidelines, education, and training on outcomes for people with diabetes detected by screening, and to quantify the effect of differences in treatment and risk factors in the first 5 years following detection. The 10-year results looked at any effects, including lasting effects on cardiovascular events, after the intensive intervention was stopped at 5 years.
"Most intervention studies informing the management of people with type 2 diabetes focus on treatment of individual risk factors, but in practice, patients receive lifestyle advice and simultaneous pharmacological treatment of several risk factors," explained Griffin.
"Most studies that have looked at multifactorial treatments tend to have been in patients with long-standing disease, whereas here we looked at whether multifactorial treatment given early after diagnosis would make a difference," he explained.
Primary care practices from Denmark, the Netherlands, and the UK used stepwise screening to identify people with previously undiagnosed type 2 diabetes.
A total of 3057 patients with newly diagnosed type 2 diabetes, according to 1999 WHO criteria, took part in the trial.
Patients were randomized to intensive management (n = 1678) and given lifestyle advice on diet, physical activity, and the importance of medication adherence and smoking cessation. Appropriate treatment was begun if A1cwas 6.5%, blood pressure was 120/80 mm Hg, and/or total cholesterol was > 3.5 mmol/L. There were also educational materials for patients and practice-based educational meetings for physicians.
Routine care (n = 1379) was based on national guidelines, and decisions around medication use were made by the individual treating clinician. The very few exclusion criteria make the study highly generalizable.
After 5 years of the intervention, there were no further efforts to encourage primary care teams to continue intensive treatment.
Patient characteristics between groups were similar. There were slightly more men than women, mean age was 60 years, around 95% were White, mean BMI was 31.6 kg/m2, approximately 6% had a history of myocardial infarction, and 28% were current smokers. Median A1c was 6.5% and 6.6% in the routine and intensive groups, respectively, mean systolic blood pressure was 149.8 and 148.5 mm Hg, and mean cholesterol was 5.6 and 5.5 mmol/L.
At 10-years post-randomization, participants were not recalled, but data on mortality, cardiovascular events, laboratory and clinical measures were collected from national registers and national audits, as well as electronic and manual searches of general practice and hospital medical records.
The primary endpoint was a composite of first cardiovascular event including cardiovascular mortality, nonfatal myocardial infarction, stroke and revascularization, and nontraumatic amputation.
Medscape Medical News reported the 5-year results from ADDITION-EUROPE in 2010. Although those in the intensive multifactorial treatment group were less likely to suffer events than those in the routine care group, the difference between groups was not statistically significant in terms of the primary endpoint.
At the time, Griffin said this likely reflected the fact that routine care of diabetes had been improving in the three countries that the patients were from. The results nevertheless illustrate that "intensive treatment in people with screen-detected diabetes is feasible," he emphasized.
For the 10-year analysis, 14 patients were lost to follow-up and 12 withdrew. Primary endpoint data were available for 99% of 3057 participants, and mean duration of follow-up was 9.6 years.
"By 10 years, the significant differences in treatments and [individual] risk factors [seen at 5 years] had largely attenuated except [those] from blood pressure medication and aspirin, which were still significantly different between groups," said Griffin at the virtual EASD.
Regarding treatment, overall, 85% of patients were prescribed antihypertensive medication, 78% statins, and 76% glucose-lowering medication (most commonly metformin).
Aspirin was used by 30.4% of the routine care group and 42.3% of the intensive treatment group. Antihypertensive agents were used by 82.4% in the routine care group and 86.4% in the intensive treatment group.
The primary endpoint at 10 years had occurred in 15.3% of patients in the routine care group versus 13.8% in the intensive treatment group.
"The small differences in treatment and risk factors seen in the first 5 years after diagnosis were associated with a nonsignificant 13% reduction (hazard ratio, 0.87; P = .14) in risk of cardiovascular disease events [composite primary endpoint] over 10 years," said Griffin when reporting the main finding.
There was also a nonsignificant 10% reduction in risk of all-cause death over 10 years (hazard ratio, 0.90); 219 patients (15.9%) in the routine care group died compared with 246 (14.7%) of those receiving intensive treatment.
"It looks like the 13% and the 10% were related to the small differences in treatment and risk factors after 5 years, suggesting a potential legacy effect," asserted Griffin.
"The UK ProspectiveDiabetesStudy has found that if you lower glucose early in disease it can have a lasting effect, whereas the effect for blood pressure, for example, only happens while on treatment. Effectively, treating people earlier will make a difference," he said.
The results overall suggest that identifying people with type 2 diabetes earlier and starting treatment promptly is beneficial, Griffin emphasized.
Also reported at the virtual EASD meeting was a study from the UK Biobank that found that 1% of individuals in the UK have undiagnosedtype 2 diabetes, and that it can take more than 5 years for people to be diagnosed.
Reporting those findings, Katherine Young, PhD, College of Medicine and Health at the University of Exeter, said the study shows "that population-level screening could identify cases of type 2 diabetes far earlier and potentially reduce complications."
Griffin said: "There is a question of how to find people and whether to do a national screening program. I suggest inviting highest risk people for screening. In the UK, the Health Checks [over 40 years] and risk assessments are sensible as long as they're being done systematically, and acted on."
Griffin has reported receiving fees from Novo Nordisk, Napp, AstraZeneca, and Eli Lilly. Sasako has reported receiving fees from Astellas, AstraZeneca, Daiichi Sankyo, MSD, Mitsubishi Tanabe, Nippon Boehringer Ingelheim, Novartis, Ono, Sanofi, Sumitomo Dainippon, Taisho Toyama, and Takeda; and grants from MSD, Nippon Boehringer Ingelheim, and Novo Nordisk. Boulton has reported no relevant financial relationships.
EASD Annual Meeting. Presented September 23, 2020.
For more diabetes and endocrinology news, follow us on Twitter and Facebook.
See the rest here:
Call to Action for Screening, Early Treatment of Diabetes - Medscape
- Fresh health warning over common additive used in thousands of ultra-processed foods including mayo and bread - Daily Mail - April 25th, 2024
- Vertex jumps to TreeFrog to enhance production of Type 1 diabetes cell therapy candidates - FiercePharma - April 25th, 2024
- Spotting the warning signs of diabetes in your pets - CBC.ca - April 25th, 2024
- Lexington-Fayette County health department organizing weekend diabetes awareness expo - WEKU - April 25th, 2024
- Preventive effects of SGLT2 inhibitors on incident hypertension in patients with diabetes who do not have hypertension ... - Nature.com - April 25th, 2024
- Curbing the Price of Novel Diabetes and Obesity Medications - Yale School of Medicine - April 25th, 2024
- Stanford Health closing Livermore Diabetes and Bariatric Center - Pleasanton Weekly - April 25th, 2024
- The association of ALT to HDL-C ratio with type 2 diabetes in 5074 years old adults: a population-based study ... - Nature.com - April 25th, 2024
- VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO ... - PR Newswire - April 25th, 2024
- Understanding the Complexity of Hyperglycemic Emergencies: Exploring the Influence of the Type and Duration of ... - Cureus - April 25th, 2024
- What Every Parent Should Know About Raising a T1D Kid - Health Central - April 25th, 2024
- Healthy Living & Diabetes Awareness Fair 2024 - University of New Mexico - April 25th, 2024
- New findings on pancreatic anatomy may affect diabetes research and treatment - Medical Xpress - April 25th, 2024
- The role of yogurt in diabetes and obesity prevention - News-Medical.Net - April 25th, 2024
- How exercising outdoors can prevent depression and diabetes - inews - April 25th, 2024
- Heart of the Valley: Valley woman discusses how she improved her health following diabetes diagnosis - KRGV - April 25th, 2024
- The Right Amount of Sleep Could Help Prevent This Extremely Common Disease - Inverse - April 25th, 2024
- 'Bread and Butter': Societies Issue T2D Management Guidance - Medscape - April 25th, 2024
- She was fired after not endorsing Splenda-filled salads to people with diabetes. Why? - The Guardian - April 25th, 2024
- Glycemic index of diets: importance beyond diabetes control - The Hindu - April 25th, 2024
- 1 woman thought she was destined for diabetes. This 1 realization helped her lose 70 pounds - Yahoo! Voices - March 29th, 2024
- Franciscan Health offering diabetes education at local churches - The Times of Northwest Indiana - March 29th, 2024
- For diabetes patients, needle-free insulin injections are on the way - ScienceBlog.com - March 29th, 2024
- Las Vegas nonprofit hosting health workshop specifically aimed at local Latinos - KTNV 13 Action News Las Vegas - March 29th, 2024
- How Often Do You Really Need to Check Your Blood Sugar Levels? - WSJ - The Wall Street Journal - March 29th, 2024
- Unintended Effects of Caps on Insulin Out-of-Pocket Costs - Managed Healthcare Executive - March 29th, 2024
- Study: Pompe treatment Nexviazyme isn't linked to new or worsening... - Pompe Disease News - March 29th, 2024
- A Smoker With New-Onset Pain in Both Feet - Medscape Reference - March 29th, 2024
- Pre-diabetes leads to Type 2 diabetes; Here's how to prevent and reverse it - WXII12 Winston-Salem - March 29th, 2024
- 'From Interpretation to Action': Using CGM to Manage T2D - Medscape - March 29th, 2024
- March: diabetes-kidney | News and features - University of Bristol - March 29th, 2024
- Health centers attempt to prevent diabetes - WTVM - March 29th, 2024
- Beyond Meat Unveils New and Expanded Line of Beyond Crumbles, Now Certified by the American Heart ... - Yahoo Finance - March 29th, 2024
- Beyond Meat Launches Revamped Plant-Based Crumbles, Earning American Heart and Diabetes Association ... - vegconomist - the vegan business magazine - March 29th, 2024
- Ypsomed hands off insulin pen needle business to focus on smart pump, autoinjector development - Fierce Biotech - March 29th, 2024
- Take the online diabetes test that could help save your life - NBC Connecticut - March 29th, 2024
- Study evaluates the use of tirzepatide in overweight/obese adults with type 1 diabetes - News-Medical.Net - March 29th, 2024
- Risk prediction using genes and gut bacteria can improve early detection of diseases like type 2 diabetes - Medical Xpress - March 29th, 2024
- On a Healthy Vegan Diet, I've Healed My Liver, Reversed Type 2 Diabetes, and Lost 35 Pounds - Forks Over Knives - March 29th, 2024
- Study Links Diet, Diabetes, and Alzheimers - Neuroscience News - March 29th, 2024
- Novo Nordisk Isn't in The "Magnificent Seven," but Here's Why I Think It Should Be - Yahoo Finance - March 18th, 2024
- Doctor warns of strange telltale sign of diabetes which can appear on the legs - The Mirror - March 18th, 2024
- Unraveling the complexities of muscle repair in diabetes: A call for targeted research and therapies - News-Medical.Net - March 18th, 2024
- Popular diabetes and weight loss drugs often hard to get for people who need them - NBC News - March 18th, 2024
- Your Health Matters: The ABCs of diabetes - The Globe | News, weather, sports from Worthington, Minnesota - The Globe - March 18th, 2024
- The Link Between Pancreatic Cancer and Diabetes - Cedars-Sinai - March 18th, 2024
- Nikita Kuzmin diabetes: what was he holding in the CBB house? - Cosmopolitan UK - March 18th, 2024
- FDA Approves Rezdiffra, the First Drug for Diabetes-Related Liver Disease - diaTribe Foundation - March 18th, 2024
- He took up running rather than take diabetes medication. It worked - South China Morning Post - March 18th, 2024
- Can Eating Yogurt Really Reduce Your Risk of Diabetes? - Health.com - March 18th, 2024
- Even short periods of diabetes remission are linked to lower risk of heart attack and stroke - The BMJ - March 18th, 2024
- Kidney stone risk factors and how type 2 diabetes medication may help - WECT - March 18th, 2024
- 'Making the Invisible Visible': CGMs Offer Insights for T2D - Medscape - March 18th, 2024
- Novo Nordisk Discontinues Insulin Medication After Cutting Its Price - The American Prospect - March 18th, 2024
- Infographic: Where GLP-1s Work Now -- and What's Coming - Medscape - March 18th, 2024
- Intermountain Health Experts Say Education Key to Prevention of Type 2 Diabetes | PRUnderground - PR Underground - March 18th, 2024
- International body recommends more sensitive test to indicate risk of developing diabetes - The Hindu - March 18th, 2024
- The importance of knowing your A1C level - KSAT San Antonio - March 18th, 2024
- Tandem Diabetes Care's t:slim X2 Insulin Pump is the First Automated Insulin Delivery System to Integrate with ... - Business Wire - January 9th, 2024
- Diffuse Alveolar Hemorrhage Occurring Suddenly in a Diabetic Patient With Asthma Exacerbation - Cureus - January 9th, 2024
- Virginia Tech researchers find drugs used to treat Type 2 diabetes reduce alcohol cravings - WRIC ABC 8News - January 9th, 2024
- FDA looking into reports of hair loss, suicidal thoughts in people using popular drugs for diabetes and weight loss - CNN - January 9th, 2024
- Glycemic control and cardiovascular outcomes in patients with diabetes and coronary artery disease according to ... - Cardiovascular Diabetology - January 9th, 2024
- Insulin price cap: More Americans will now pay no more than $35 - USA TODAY - January 9th, 2024
- Eli Lilly cracks down on the use of weight loss drugs Mounjaro and Zepbound for cosmetic reasons instead of for diabetes and obesity - Fortune - January 9th, 2024
- No Increased Risk of Suicidal Ideation With GLP-1 Drugs - Medpage Today - January 9th, 2024
- Ask the Doctors | New research being conducted to treat diabetes - Eureka Times-Standard - January 9th, 2024
- Salivary Chloride Intracellular Channel 1 (CLIC1) as a Hub of Gene-Gene Interactome of Periodontitis With Diabetes ... - Cureus - January 9th, 2024
- Why Omada's CEO Thinks Amazon Selected His Startup as the 1st Partner for Its New Program - MedCity News - January 9th, 2024
- Researchers find drugs used to treat type 2 diabetes and obesity reduce alcohol cravings - Medical Xpress - January 9th, 2024
- Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different ... - Nature.com - January 9th, 2024
- CV Safety Profile of TheracosBio's BRENZAVVY (bexagliflozin) Confirmed in Research Published in Diabetes ... - Business Wire - January 9th, 2024
- 6 "Bad" Fruits You Should Be Eating When You Have Diabetes, According to Dietitians - EatingWell - January 9th, 2024
- Children of Women with Type 1 Diabetes Have Increased Heart Defect Risk - Inside Precision Medicine - January 9th, 2024
- Transforming Corporate Health: Fitterfly's Success in Tackling Diabetes and Weight Issues - Business Standard - January 9th, 2024
- Ozempic and weight loss | News and views - Diabetes UK - January 9th, 2024
- Drugs used to treat Type 2 diabetes reduce alcohol cravings - ScienceBlog.com - January 9th, 2024
- People taking Wegovy and Ozempic have lower risk of suicidal thoughts vs. older drugs, study finds - ABC News - January 9th, 2024
- For Those With Diabetes On Medicare Part D, Insulin Is $35...If Its Covered - Forbes - October 27th, 2023
- Biologist Douglas Melton: I was studying frogs until my son was diagnosed with diabetes then I started looking for a cure - EL PAS USA - October 27th, 2023